The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Open accessAbstract
BACKGROUND: Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS: In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the upper limit of the normal range to receive subcutaneous pasireotide at a dose of 600 μg (82 patients) or 900 μg (80 patients) twice daily. Patients with urinary free cortisol not exceeding 2 times the upper limit of the normal range and not exceeding the baseline level at month 3 continued to receive their randomly assigned dose; all others received an additional 300 μg twice daily. The primary end point was a urinary free cortisol level at or below the upper limit of the normal range at month 6 without an increased dose. Open-label treatment continued through month 12. RESULTS: Twelve of the 82 patients in the 600-μg group and 21 of the 80 patients in the 900-μg group met the primary end point. The median urinary free cortisol level decreased by approximately 50% by month 2 and remained stable in both groups. A normal urinary free cortisol level was achieved more frequently in patients with baseline levels not exceeding 5 times the upper limit of the normal range than in patients with higher baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, and clinical signs and symptoms of Cushing's disease diminished. Pasireotide was associated with hyperglycemia-related adverse events in 118 of 162 patients; other adverse events were similar to those associated with other somatostatin analogues. Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatment initiation and then stabilized; treatment with a glucose-lowering medication was initiated in 74 of 162 patients. CONCLUSIONS: The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropin-secreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mean UFC is routinely used in clinical practice and research to monitor disease control and treatment response in patients with CS treated with medical therapy (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The restoration of cortisol circadian rhythm following medical therapy has not been investigated or established for most medications used to treat CS, and it is not routinely measured to determine treatment response (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In clinical trials, the efficacy of steroidogenesis inhibitors and pituitary-directed therapies in patients with CS was primarily evaluated by the normalization of cortisol secretion per UFC (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Self-citationNewell-Price, J. D. C., BERTAGNA, X. Y., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,258
Self-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationIncidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Morbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.117 · Cited by 505
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474
Pivonello, R., Martino, M. C. D., Cappabianca, P., Leo, M. D., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Cavagnini F, 2001, Ann Endocrinol (Paris), 62, 168
Cited by
Sorted by citations
Items 501–600 of 625
White, P. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-31107-4_25 · Cited by 1
Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line
Gentilin, E., de Souza, P. B., Ambrosio, M. R., Bondanelli, M., Gagliardi, I., & Zatelli, M. C. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02117-0 · Cited by 1
Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy
Kageyama, K., & Nishiyama, M. (2023) · Cancers · doi:10.3390/cancers15235526 · Cited by 1
Clinical Perspective: What Do Addison and Cushing Tell Us About Glucocorticoid Action?
Harris, C. A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2895-8_4 · Cited by 1
Diabetes Associated with Glucocorticoid Excess
Janssen, J. A. M. J. L., & Lamberts, S. W. J. (2014) · Frontiers in diabetes · doi:10.1159/000357244 · Cited by 1
Endocrine metabolism III: adrenal glands
Ha, C. E., & Bhagavan, N. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88541-6.00001-6 · Cited by 1
Резніков, А. Г. (1990) · PubMed · Cited by 1
Update on the use of oral octreotide therapy for acromegaly
Schilbach, K., & Schopohl, J. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1199954 · Cited by 1
Writers, A. M. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0315-4 · Cited by 1
Pathogenesis and Treatment of Aggressive Corticotroph Pituitary Tumors
Shen, Y., & Heaney, A. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_5 · Cited by 1
Medical Therapies in Cushing’s Syndrome
Tritos, N. A., & Biller, B. M. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_9 · Cited by 1
Self-citationDiabète induit par les somatostatinergiques
Vergès, B. L. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30208-5 · Cited by 1
Efficacy of pasireotide in controlling severe hypercortisolism until cardiac transplantation
Attanasio, R., Cortesi, L., Gianola, D., Vettori, C., Sileo, F., & Trevisan, R. (2017) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0140 · Cited by 1
Radiation Therapy in Tumors of the Pituitary Gland
Bajaj, A., Solanki, A. A., Miller, C. E., Altoos, B., Giordano, F. A., & Shih, H. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-52619-5_6-1 · Cited by 1
Les nouveaux traitements médicamenteux de la maladie de Cushing
BERTAGNA, X. Y. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30515-1 · Cited by 1
Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Bousquet, C., Castano, J. P., Csaba, Z., Culler, M., Dournaud, P., Epelbaum, J., Feniuk, W., Harmar, A. J., Hills, R., Hofland, L. J., et al. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f61/2019.4 · Cited by 2
Клинични ползи и финансова тежест на pasireotidе
Камушева, М., Въндева, С., Elenkova, A. P., Zakharieva, S., & Петрова, Г. (2019) · Редки болести и лекарства сираци · doi:10.36865/2019.v10i2.70 · Cited by 1
Hyperglycemia Secondary to Nondiabetic Conditions and Therapies
Lebovitz, H. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00042-1 · Cited by 1
Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
Machado, M. C., Cescato, V. Â. S., Fragoso, M. C. B. V., & Bronstein, M. D. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2021.02.007 · Cited by 1
Pituitary Tumors: Diagnosis and Management
Madan, R., Yadav, A., & Goyal, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-2659-3_31 · Cited by 1
Shen, A., King, J. A. J., Colman, P. G., & Yates, C. J. (2021) · Future Rare Diseases · doi:10.2217/frd-2021-0007 · Cited by 1
Tauchmanovà, L., Breitschaft, A., Holder, G., Han, K. T., Choudhury, S., Darstein, C., Paul, M., Drutinus, E., Gericke, G., SCHMID, H. A., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02908-6 · Cited by 1
Physiopathology, Diagnosis, and Treatment of Hypercortisolism
Pivonello, R., Iacuaniello, D., Simeoli, C., Martino, M. C. D., & Colao, A. (2018) · Endocrinology · doi:10.1007/978-3-319-44444-4_12 · Cited by 1
Self-citationPituitary Tumor Treatment with Somatostatin Analogues
Hubalewska–Dydejczyk, A., Gilis‐Januszewska, A., & Trofimiuk–Müldner, M. (2015) · doi:10.1002/9781119031659.ch16 · Cited by 1
Italian Society of Endocrinology Career Award Lecture: from somatostatin to…somatomedin.
Ferone, D. (2012) · PubMed · doi:10.3275/8583 · Cited by 1
DIAGNÓSTICO Y TRATAMIENTO DE TUMORES NEUROENDOCRINOS PRODUCTORES DE ACTH.
Ovalles, M. A., Vera, L., & Olivieri, M. B. (2014) · Actualidad Contable FACES · Cited by 1
Karppinen, A. (2015) · Työväentutkimus Vuosikirja · Cited by 1
Diagnosis and Clinical Management of Aggressive Pituitary Tumors
Raverot, G., Jouanneau, E., & Trouillas, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64308-8 · Cited by 1
ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J. S., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50015-2 · Cited by 1
Long-Term Complications of Hypercortisolism
Pivonello, R., Iacuaniello, D., Simeoli, C., Martino, M. C. D., & Colao, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64305-2 · Cited by 1
Self-citationReceptores de somatostatina en tumores hipofisarios
Huertas, R. M. L., Ortiz, M. D. G., Costa, A. I., & Fuentes, J. P. C. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-538-7.00003-4
Hyernard, C. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.11.016
Lawrence, B. J., Anderson, Schimmack, Findlay, Kidd, & Modlin (2012) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s21939
Manejo de la enfermedad de Cushing persistente tras cirugía
Rodríguez, J. S. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-538-7.00010-1
Wójcik, M., Tyrawa, K., Kalicka-Kasperczyk, A., Zygmunt-Górska, A., & Starzyk, J. (2014) · Endocrine Practice · doi:10.4158/ep13497.cr
Interview with Dr André Lacroix
Lacroix, A. (2014) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.9
Tratamiento médico de tumores hipofisarios
Becker, C. P. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70218-9
Lin, J., Deng, A., Hoffman-Censits, J. H., Gibney, G. T., Hyslop, T., Miller, B., Kilpatrick, D. L., Jabbour, S. A., & Kelly, W. K. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.11.003
Murray, R. D. (2015) · Springer eBooks · doi:10.1007/978-1-4471-2789-5_6
MÁSTER EN INVESTIGACIÓN BIOMÉDICA TRASLACIONAL
Castano, J. P., Luque, R. M., & Gahete, M. D. (2013)
Surgical Management of Adrenocorticotropic Hormone-Secreting Pituitary Adenomas
Kulubya, E. S., Donoho, D. A., Carmichael, J. D., & Zada, G. (2016) · International Journal of Endocrine Oncology · doi:10.2217/ije.15.26
TRABAJOS ESPECIALES MANEJO DE PACIENTES CON SÍNDROME DE CUSHING.
Lima-Martínez, M. M., Zerpa, J., Guerrero, Y., Rivera, J., & Vielma, M. (2013)
Pharmacological Treatment for Pituitary Adenomas
Tominaga, A., Kinoshita, Y., Usui, S., & Kurisu, K. (2013) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.22.101
Yedinak, C. G., Brzana, J. A., McCartney, S., & Fleseriu, M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_3
Manejo de los tumores hipofisarios agresivos
Aller, J., Michelena, M. C., García, N. P., & García, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-538-7.00011-3
Pituitary and Adrenal Disorders in Pregnancy
Molitch, M. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-32108-2.00043-3
Acute Thyroid and Adrenal Disorders
Subrahmanyam, P. E. R. (2016) · Springer eBooks · doi:10.1007/978-81-322-2710-6_31
Tsagarakis, S. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch2
Genetic Factors in Cushing Disease Pathogenesis
Parsa, A. A., & Melmed, S. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00031-4
Trofimiuk–Müldner, M., & Hubalewska–Dydejczyk, A. (2015) · doi:10.1002/9781119031659.ch1
Evaluation and Management of Cushing's
Feelders, R. A. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch33
Posttreatment Management of Cushing’s Disease
Prete, A., & Salvatori, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00009-7
Auchus, R. J. (2014) · Encyclopedia of the Neurological Sciences · doi:10.1016/b978-0-12-385157-4.01208-2
Yuen, K. C. J., Mercado, J. U., Moloney, K. J., & Broyles, F. E. (2017) · AACE Clinical Case Reports · doi:10.4158/ep171745.cr
Giraldi, F. P. (2017) · L Endocrinologo · doi:10.1007/s40619-017-0331-1
A neuroendokrin tumorok gyógyszeres kezelése
Tóth, M. (2013)
Hypophysenadenome – nicht immer benigner Natur
Petersenn, S. (2017) · Der Onkologe · doi:10.1007/s00761-017-0319-2
Self-citationPhysiopathology, Diagnosis, and Treatment of Hypercortisolism
Pivonello, R., Iacuaniello, D., Simeoli, C., Martino, M. C. D., & Colao, A. (2017) · Endocrinology · doi:10.1007/978-3-319-38681-2_12-1
Self-citationCushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?
Witek, P., Mazur, M., & Witek, J. (2017) · Oncoreview · doi:10.24292/01.or.211217
Prevention, diagnosis and treatment of Nelson's syndrome
Sala, E., Ho, A. L., Azad, T. D., Veeravagu, A., & Katznelson, L. J. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.01.001
Modern views on Cushing’s disease treatment
Kadzharyan, V. G., & Soloviuk, O. O. (2018) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2018.02.125354
La terapia medica della Malattia di Cushing: presente e futuro
Ceccato, F., Lizzul, L., & Scaroni, C. M. (2018) · L Endocrinologo · doi:10.1007/s40619-018-0441-4
Majewski, C. (2018) · Difficult decisions in surgery: an evidence-based approach · doi:10.1007/978-3-319-92860-9_26
Neuroendocrine Disorders in Women
Lovett, A. J., & Woodmansee, W. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-04245-5_5
Evaluación positiva de medicamentos: 1 er trimestre 2012
Técnica, N., Alfonso, M. G., OLIVÁN, P. P., Luque, A. G., & Vicente, M. P. (2012)
Диагностика и лечение гипофизарного синдрома Кушинга
Kirilyuk, M. L. (2014) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.6.62.2014.76950
Les traitements du syndrome de Cushing
Beaudoin, M. A., & Schillo, F. (2019) · Actualités Pharmaceutiques · doi:10.1016/j.actpha.2019.02.007
Innovative Methods for Some Statistical Issues in Clinical Trials
Lam, D. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/mbpc-1623
A Stratified Approach for Cushing’s Syndrome Diagnosis
Chávez-Castillo, M., Rojas, J., Aguirre, M., Villalobos, M., Salazar, J. J., Bello, L., Áñez, R., Olivar, L. C., Calvo, M. C. C., Herazo-Beltrán, Y., et al. (2019) · Global Journal of Health Science · doi:10.5539/gjhs.v11n10p55
Pituitary Adenomas: Evaluation and Management From a Surgical Perspective
Maggio, W., & Shargorodsky, J. (2020) · Advances in Treatment and Management in Surgical Endocrinology · doi:10.1016/b978-0-323-66195-9.00021-2
Factors Influencing Job Promotion in Iranian Nursing Profession, Barriers and Facilitators
Mirmohammadi, F., Hoseini, M. A. S., Yazdani, H. R., & Ebadi, A. (2019) · Preventive Care In Nursing and Midwifery Journal · doi:10.29252/pcnm.9.1.58
Cushing's syndrome and acromegaly based on picoadenoma of the pituitary gland
Ságová, I., Kantárová, D., Pávai, D., Dragula, M., Vaňuga, A., & Vaňuga, P. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.040
Endoscopic Approach for Pituitary Tumours - Outcome and Complications - An Institutional Experience
Kamatagi, V., Attry, S., Gupta, V., Gupta, E., & Carvalho, A. S. (2020) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2020/454
Balentine, C. J., & Sippel, R. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-13662-2_35
Pasireotid: Eine neue Therapieoption bei Morbus Cushing
Luger, A., Rw, G., Hofmann, A. F., Höfle, G., Pichler, R., Piswanger-Sölkner, J. C., & Schnack, C. (2012) · Journal für Kardiologie (Krause & Pachernegg GmbH)
8 Natural History and Management Options for Cushing’s Disease Cushing’s disease
(2021) · Thieme Medical Publishers eBooks · doi:10.1055/b-0041-184139
Tulipano, G., & Schulz, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_137
Diabetes Secondary to Endocrine Disorders
Tomlinson, J. (2022) · doi:10.1093/med/9780198870197.003.0271
Newell-Price, J. D. C. (2022) · doi:10.1093/med/9780198870197.003.0101
Self-citationAlexandraki, K., & Grossman, A. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_8
Ioachimescu, A. G., & Oyesiku, N. M. (2018) · doi:10.1002/9781118592168.ch38
White, P. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-31420-4_25-1
Kaimal, N., & Trainer, P. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_7
Laws, E. R., Woodmansee, W. W., & Loeffler, J. S. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780199651870.003.0018
Somatostatin (growth hormone release-inhibiting hormone) and analogues
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01459-1
Donoho, D. A., & Zada, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00020-9
Fleseriu, M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_1
Tulipano, G., & Schulz, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_137-1
Blount, S. L., & Silverstein, J. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_22
Tovar, A. P., Abreu-Lomba, A., Arenas-Quintero, H. M., Giraldo, C. M. G., Pantoja, D., Valenzuela, Á., Ramos, A. F. G., & Gómez, N. B. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.3.738
Neoplasms of the Endocrine Glands and Pituitary Neoplasms
Feng, R., Gandhi, C. D., Pain, M., & Post, K. D. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm080.pub2
Prospettive future nella terapia della Sindrome di Cushing
Pivonello, C., Simeoli, C., Patalano, R., Paola, N. D., & Pivonello, R. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01202-5
Pereira, A. M., & Dekkers, O. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00006-8
Pituitary Neuroendocrine Tumors
(2020) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477916-03
Genetic factors in Cushing disease pathogenesis
Liu, N., Parsa, A. A., & Melmed, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00032-0
Huang, C.-J., Lu, C.-H., & Shih, K.-C. (2023) · European journal of drug metabolism and pharmacokinetics · doi:10.1007/s13318-023-00854-4
Quarde, A. (2023) · doi:10.1002/9781119863564.ch1
Metadata
- Authors
- Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., & Biller, B. M. K.
- Affiliations
- Federico II University Hospital (IT)
- University of Duisburg-Essen (DE)
- University of Sheffield (GB)
- Medical College of Wisconsin (US)
- Peking Union Medical College Hospital (CN)
- Novartis (Switzerland) (CH)
- Universidade de São Paulo (BR)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 914-924
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133418708
- Semantic Scholar
- d3443b929babd2daf7d6ae90395d546356fda173
- Cited by
- 628
- References
- 22
- Citations by year
- 2026: 13 · 2025: 31 · 2024: 28 · 2023: 28 · 2022: 33 · 2021: 35 · 2020: 32 · 2019: 41 · 2018: 46 · 2017: 46 · 2016: 52 · 2015: 66 · 2014: 68 · 2013: 77 · 2012: 29
- FWCI
- 61.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- pasireotide, Cushing's disease, somatostatin receptor type 5, somatostatin analogues, urinary free cortisol, hypercortisolism, hyperglycemia, HbA1c, dose escalation
- MeSH terms
- Adolescent, Adrenocorticotropic Hormone, Adult, Aged, Child, Double-Blind Method, Female, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Saliva, Somatostatin, Pituitary ACTH Hypersecretion, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
